3 / 16
2
Q2 2016
Announced M&A Transactions
Completed
Completed
Completed
June 3, 2016
June 1, 2016
May 13, 2016
Notes
Notes
Notes
According to the agreement, “Baxalta
shareholders will receive $18.00 in cash and
0.1482 Shire ADS per Baxalta share. Based on
Shire’s closing ADS price on January 8, 2016, this
implies a total current value of $45.57 per Baxalta
share, representing an aggregate consideration of
approximately $32 billion. The exchange ratio is
based on Shire’s 30-day trading day volume
weighted average ADS price of $199.03 as of
January 8, 2016, which implies a total value of
$47.50 per Baxalta share.”
The purchase price consists of $720
million of cash consideration, a $100
million long-term subordinated
promissory note with interest paid in
kind, and other contingent consideration.
Upon closing, Verisk Health will be
renamed and will operate as an
independent company at its current
headquarters in Waltham, MA. The buy
side termination fee is $57.4 million.
Under the terms of the purchase
agreement, DiaSorin will pay to Quest
Diagnostics $300 million in cash for all
the tangible and intangible assets of
Focus used by the Company to develop,
manufacture and distribute its molecular
diagnostic products and its traditional
immunoassay ELISA products, including
among other relevant intellectual
property, contracts and customer list. The
deal does not include Quest’s diagnostic
information service laboratories currently
operating under the Focus Diagnostics
brand. Those labs will continue to be
based in San Juan Capistrano, CA, as
part of Quest.
Source: Public Filings; Industry Newswires and Capital IQ as of 6/22/16
acquired
acquired
acquired